

# Leona Plum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3309036/publications.pdf>

Version: 2024-02-01

31  
papers

4,548  
citations

304743

22  
h-index

434195

31  
g-index

31  
all docs

31  
docs citations

31  
times ranked

6443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Agouti-related peptide-expressing neurons are mandatory for feeding. <i>Nature Neuroscience</i> , 2005, 8, 1289-1291.	14.8	663
2	A guide to analysis of mouse energy metabolism. <i>Nature Methods</i> , 2012, 9, 57-63.	19.0	655
3	Insulin Action in AgRP-Expressing Neurons Is Required for Suppression of Hepatic Glucose Production. <i>Cell Metabolism</i> , 2007, 5, 438-449.	16.2	579
4	The role of insulin receptor signaling in the brain. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 59-65.	7.1	512
5	Central insulin action in energy and glucose homeostasis. <i>Journal of Clinical Investigation</i> , 2006, 116, 1761-1766.	8.2	352
6	Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity. <i>Journal of Clinical Investigation</i> , 2006, 116, 1886-1901.	8.2	281
7	FoxO1 Target Gpr17 Activates AgRP Neurons to Regulate Food Intake. <i>Cell</i> , 2012, 149, 1314-1326.	28.9	164
8	The obesity susceptibility gene <i>Cpe</i> links FoxO1 signaling in hypothalamic pro-opiomelanocortin neurons with regulation of food intake. <i>Nature Medicine</i> , 2009, 15, 1195-1201.	30.7	150
9	Peripheral Hyperinsulinemia Promotes Tau Phosphorylation In Vivo. <i>Diabetes</i> , 2005, 54, 3343-3348.	0.6	131
10	Divergent Regulation of Energy Expenditure and Hepatic Glucose Production by Insulin Receptor in Agouti-Related Protein and POMC Neurons. <i>Diabetes</i> , 2010, 59, 337-346.	0.6	130
11	Enhanced Leptin-Stimulated Pi3k Activation in the CNS Promotes White Adipose Tissue Transdifferentiation. <i>Cell Metabolism</i> , 2007, 6, 431-445.	16.2	121
12	Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 179-188.	11.4	116
13	Single copy shRNA configuration for ubiquitous gene knockdown in mice. <i>Nucleic Acids Research</i> , 2005, 33, e67-e67.	14.5	101
14	Myeloid Cell-Restricted Insulin Receptor Deficiency Protects Against Obesity-Induced Inflammation and Systemic Insulin Resistance. <i>PLoS Genetics</i> , 2010, 6, e1000938.	3.5	92
15	Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E867-E871.	3.6	77
16	Comparison of Glucostatic Parameters After Hypocaloric Diet or Bariatric Surgery and Equivalent Weight Loss. <i>Obesity</i> , 2011, 19, 2149-2157.	3.0	67
17	Euglycaemic glucose clamp: what it can and cannot do, and how to do it. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 962-972.	4.4	67
18	Oral Insulin Reloaded. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 458-465.	2.2	59

#	ARTICLE	IF	CITATIONS
19	gp130 signaling in proopiomelanocortin neurons mediates the acute anorectic response to centrally applied ciliary neurotrophic factor. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10707-10712.	7.1	52
20	Effect of Hyperinsulinemia and Type 2 Diabetes-Like Hyperglycemia on Expression of Hepatic Cytochrome P450 and GlutathioneS-Transferase Isoforms in a New Zealand Obese-Derived Mouse Backcross Population. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 442-450.	2.5	35
21	Diet-dependent obesity and hypercholesterolemia in the New Zealand obese mouse: identification of a quantitative trait locus for elevated serum cholesterol on the distal mouse chromosome 5. Biochemical and Biophysical Research Communications, 2003, 304, 812-817.	2.1	33
22	The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects. Clinical Pharmacokinetics, 2019, 58, 1497-1504.	3.5	23
23	Blunted Refeeding Response and Increased Locomotor Activity in Mice Lacking FoxO1 in Synapsin-1-Expressing Neurons. Diabetes, 2013, 62, 3373-3383.	0.6	21
24	InsR/FoxO1 Signaling Curtails Hypothalamic POMC Neuron Number. PLoS ONE, 2012, 7, e31487.	2.5	16
25	Effects on $\beta$ - and $\alpha$ -cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: a n exploratory mechanistic study. Diabetes, Obesity and Metabolism, 2017, 19, 489-495.	4.4	16
26	Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. Clinical Therapeutics, 2020, 42, 1762-1777.e4.	2.5	12
27	Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study. Hormone and Metabolic Research, 2018, 50, 403-407.	1.5	8
28	Better glycaemic control with BioChaperone glargine lispro co $\alpha$ formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1570-1575.	4.4	5
29	Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8. Diabetes Technology and Therapeutics, 2017, 19, 463-470.	4.4	4
30	Pharmacological Intervention in Type 2 Diabetes Mellitus - A Pathophysiologically Reasoned Approach?. Current Diabetes Reviews, 2016, 12, 429-439.	1.3	4
31	Injecting without pressing a button: An exploratory study of a shield $\alpha$ triggered injection mechanism. Diabetes, Obesity and Metabolism, 2018, 20, 1140-1147.	4.4	2